These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33725120)

  • 1. What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?
    Nakafero G; Grainge MJ; Card T; Mallen CD; Zhang W; Doherty M; Taal MW; Aithal GP; Abhishek A
    Rheumatology (Oxford); 2021 Dec; 60(12):5785-5794. PubMed ID: 33725120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
    Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM
    Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of less frequent monitoring of liver transaminases levels in rheumatic patients treated with low-dose methotrexate.
    Khabbazi A; Kolahi S; Dastgiri S; Hajialiloo M; Nazeri M; Nazeri L; Sheikholeslami Salmasi A; Gader S; Bak Mohammad Zadeh S; Ghasemi A; Poormohammad A
    Int J Rheum Dis; 2014 Jul; 17(6):646-52. PubMed ID: 24965662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate.
    Malesci D; Tirri R; Buono R; La Montagna G
    Clin Exp Rheumatol; 2007; 25(6):881-4. PubMed ID: 18173924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leflunomide Increases Hepatic Exposure to Methotrexate and Its Metabolite by Differentially Regulating Multidrug Resistance-Associated Protein Mrp2/3/4 Transporters via Peroxisome Proliferator-Activated Receptor
    Wang L; Ma L; Lin Y; Liu X; Xiao L; Zhang Y; Xu Y; Zhou H; Pan G
    Mol Pharmacol; 2018 Jun; 93(6):563-574. PubMed ID: 29618584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate.
    Alves JA; Fialho SC; Morato EF; Castro GR; Zimmermann AF; Ribeiro GG; Neves FS; Pereira IA
    Rev Bras Reumatol; 2011; 51(2):141-4. PubMed ID: 21584420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT.
    Stouten V; Michiels S; Westhovens R; De Cock D; Belba A; Pazmino S; Van der Elst K; Joly J; Verschueren P
    Clin Rheumatol; 2020 Sep; 39(9):2593-2601. PubMed ID: 32166429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate.
    Shin K; Baek HJ; Kang YM; Cha HS; Kang SW; Park SH; Jun JB; Lee YJ; Choi IA; Song YW
    Int J Rheum Dis; 2019 Jun; 22(6):1115-1122. PubMed ID: 30861334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha.
    De Stefano R; Frati E; Nargi F; Baldi C; Menza L; Hammoud M; Galeazzi M
    Clin Rheumatol; 2010 May; 29(5):517-24. PubMed ID: 20082236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-arthritic effect of β-caryophyllene and its ameliorative role on methotrexate and/or leflunomide-induced side effects in arthritic rats.
    El-Sheikh SMA; Abd El-Alim AEF; Galal AAA; El-Sayed RG; El-Naseery NI
    Life Sci; 2019 Sep; 233():116750. PubMed ID: 31408659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum.
    Nakafero G; Grainge MJ; Card T; Mallen CD; Riley R; van der Windt D; Fox CP; Taal MW; Aithal GP; Williams HC; Abhishek A
    Rheumatol Adv Pract; 2022; 6(2):rkac046. PubMed ID: 35702565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F; Michaud K; Stephenson B; Doyle J
    J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.
    Bird P; Griffiths H; Tymms K; Nicholls D; Roberts L; Arnold M; Burnet S; de Jager J; Scott J; Zochling J; Littlejohn G
    J Rheumatol; 2013 Mar; 40(3):228-35. PubMed ID: 23322457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis.
    Benucci M; Saviola G; Baiardi P; Manfredi M; Sarzi-Puttini P; Atzeni F
    Int J Immunopathol Pharmacol; 2011; 24(1):269-74. PubMed ID: 21496415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
    Kremer J; Genovese M; Cannon GW; Caldwell J; Cush J; Furst DE; Luggen M; Keystone E; Bathon J; Kavanaugh A; Ruderman E; Coleman P; Curtis D; Kopp E; Kantor S; Weisman M; Waltuck J; Lindsley HB; Markenson J; Crawford B; Fernando I; Simpson K; Strand V
    J Rheumatol; 2004 Aug; 31(8):1521-31. PubMed ID: 15290730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumatica.
    Vinicki JP; Cusa A; Domingo D; Velasco Zamora JL; Magri S; Brigante A; Schmid MM; Ávila P; Zamora N; Sorrentino L; Rodriguez AM; Linarez M; Pisoni C; Costi C; Rodriguez Gil G; Spinetto MA; Paris VU; Perrotta N; Maliandi MDR; Rillo O; Pena C; Got J; Cavallasca J; Machado Escobar M; Iturralde C; Martire MV; Tessel R; Chocobar NS; Alarcon G
    Rheumatol Adv Pract; 2024; 8(2):rkae033. PubMed ID: 38560643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate plus leflunomide for the treatment of relapsingWegener's granulomatosis. A retrospective uncontrolled study.
    Bremer JP; Ullrich S; Laudien M; Gross WL; Lamprecht P
    Clin Exp Rheumatol; 2010; 28(1 Suppl 57):67-71. PubMed ID: 20412706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.
    Aletaha D; Stamm T; Kapral T; Eberl G; Grisar J; Machold KP; Smolen JS
    Ann Rheum Dis; 2003 Oct; 62(10):944-51. PubMed ID: 12972472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
    Chen Z; Li XP; Li ZJ; Xu L; Li XM
    Int Immunopharmacol; 2013 Mar; 15(3):474-7. PubMed ID: 23415907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.